Table 2.
Univariate and multivariate analyses to assess whether there is an association between epilepsy and seropositivity to Toxocara in people.
| Study Participants | Number Seropositive (%) | Number Seronegative (%) | Univariate Analysis OR (95% CI) * |
Multivariate Analysis OR (95% CI) * |
|---|---|---|---|---|
| Total no. epileptic patients | 37 (39.36) | 57 (60.64) | 1.86 (1.14–3.23) | 2.38 (1.25–4.63) |
| Number of healthy controls | 23 (26.44) | 64 (73.56) | 1 | 1 |
| Partial epilepsy | 12 (41.9) | 16 (57.1) | 2.04 (1.12–4.21) | 2.60 (1.14–6.04) |
| Healthy controls | 23 (26.14) | 65 (73.86) | 1 | 1 |
| Generalized epilepsy | 25 (37.9) | 41 (62.1) | 1.79 (1.08–3.21) | 2.17 (1.09–4.40) |
| Healthy controls | 23 (26.14) | 65 (73.86) | 1 | 1 |
| Partial epilepsy | 12 (41.9) | 16 (57.1) | 1.58 (0.93–3.02) | 1.38 (0.63–3.01) |
| Generalized epilepsy | 25 (37.9) | 41 (62.1) | 1 | 1 |
* Crude or adjusted odds ratios (ORs) estimated by approximate Bayesian logistic regression employing a penalized likelihood (PL) estimation via data augmentation [28]; the final multivariable models were adjusted for the following risk factors: age, sex, relatives’ history of epilepsy, and history of epilepsy in a parent.